FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Complete Response on Immunomedics Breast Cancer BLA

FDA issues Immunomedics a complete response letter on its BLA for sacituzumab govitecan for treating patients with metastatic triple-negative breast c...

FDA General

More Furloughs, Discretionary Cuts Expected: Gottlieb

FDA commissioner Scott Gottlieb says the agency is curbing discretionary activities and looking to order furloughs in areas where the workload has dro...

Human Drugs

Clinical Benefit Not Proven with Lillys Lartruvo

Eli Lilly says a Phase 3 study of Lartruvo (olaratumab), in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma, ...

Medical Devices

Medtronic Synergy Cranial Software Class 1 Recall

FDA classifies as Class 1 a Medtronic recall of its Synergy Cranial Software and Stealth Station S7 Cranial Software due to reports of incorrect infor...

Human Drugs

Prinston Pharmaceutical Recalls Irbesartan Due to Impurity

Prinston Pharmaceutical Inc. recalls one lot of irbesartan and seven lots of irbesartan hydrochlorothiazide tablets due to the detection of trace amou...

Biologics

FDA Approves Mercks Herceptin Biosimilar

FDA approves Mercks Ontruzant (trastuzumab-dttb) as a biosimilar to Genentechs Herceptin (transtuzumab) for patients with HER2-overexpressing breast c...

FDA General

FDA WEBVIEW CLOSED FOR MLK DAY

FDA Webviews newsroom closes Monday (1/21) in observance of Martin Luther King day.

Medical Devices

FDA Clears EBM Tech Radiological Image Reader

FDA clears an EBM Technologies 510(k) for its iPad Pro-based Rad System for diagnostic reading of radiological images.

Medical Devices

FDA Safety Issue with Paclitaxel-coated Balloons and Stents

FDA says it is evaluating recent information regarding the potential for increased long-term mortality after use of paclitaxel-coated balloons and pac...

Human Drugs

Complete Response Letter to Actelion for Opsumit sNDA

FDA issues Actelion Pharmaceuticals a complete response letter for its supplemental NDA for Opsumit (macitentan) for treating adults with inoperable c...